Table 2 PABAK – OS – 3-level interpretation
Drug Class | Drug | Proportion observed agreement | Minor discrepancy | Major discrepancy | PABAK-OS | 95%CI of PABAK-OS |
|---|---|---|---|---|---|---|
NNRTI | Etravirine | 0.99 | 18 | 1 | 0.98 | (0.96 - 1.01) |
NRTI | Abacavir | 0.98 | 20 | 0 | 0.98 | (0.96 - 1.01) |
Didanosine | 0.99 | 19 | 0 | 0.98 | (0.96 - 1.01) | |
Lamivudine | 1.00 | 1 | 0 | 1.00 | (0.97 - 1.03) | |
Stavudine | 0.99 | 16 | 0 | 0.99 | (0.96 - 1.01) | |
Tenofovir | 1.00 | 5 | 0 | 1.00 | (0.97 - 1.02) | |
Zidovudine | 0.98 | 21 | 0 | 0.98 | (0.95 - 1.01) | |
PI | Atazanavir/r | 1.00 | 5 | 0 | 1.00 | (0.97 - 1.02) |
Darunavir/r | 1.00 | 0 | 0 | 1.00 | (0.97 - 1.03) | |
Lopinavir/r | 1.00 | 2 | 0 | 1.00 | (0.97 - 1.03) | |
Saquinavir/r | 1.00 | 2 | 0 | 1.00 | (0.97 - 1.03) | |
Tipranavir/r | 1.00 | 4 | 0 | 1.00 | (0.97 - 1.02) |